SEPN

Septerna, Inc. Common Stock

SEPN

Market cap $645M

Overview Fund Activity

14.44 USD

-0.03

0.21%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

14.44

0.00

0%

1 day

-0.21%

5 days

-5.93%

1 month

24.59%

3 months

37%

6 months

127.76%

Year to date

-32.37%

1 year

-32.52%

5 years

-32.52%

10 years

-32.52%

About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Employees: 75

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

317% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 6

79% more capital invested

Capital invested by funds: $262M [Q1] → $470M (+$207M) [Q2]

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

25% more funds holding

Funds holding: 71 [Q1] → 89 (+18) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

2.2% less ownership

Funds ownership: 101.91% [Q1] → 99.71% (-2.2%) [Q2]

97% less call options, than puts

Call options by funds: $440K | Put options by funds: $12.6M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

73% upside

Avg. target

$26

77% upside

High target

$26

80% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Josh Schimmer	$25	Overweight Reiterated	5 Sep 2025
HC Wainwright & Co. Raghuram Selvaraju	$26	Buy Reiterated	21 Aug 2025

See Analyst Rankings

Financial journalist opinion

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following upcoming investor conferences in September:

Septerna to Participate in Upcoming Investor Conferences

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM) being developed for the treatment of chronic spontaneous urticaria (CSU) and other mast cell-driven diseases.

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the second quarter ended June 30, 2025.

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

On Monday, HC Wainwright initiated coverage on Septerna, Inc. SEPN, citing a next-generation drug design platform aimed at hitherto-undruggable targets.

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.

Septerna to Present at Jefferies Global Healthcare Conference

Analysts Think These Stocks Could More Than Double in Value

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.

Analysts Think These Stocks Could More Than Double in Value

Zacks Investment Research

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require additional funding, potentially diluting current shareholders.

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™